Fiscal Year 2024 Department of Defense Glioblastoma Research Program (GBMRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Hypothesis Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: HT942524GBMRPHDA	Independent investigators at all career levels (or equivalent). Early-career investigators (defined as independent, non-mentored investigators at least 2 years beyond their last training position) are encouraged to apply.	 Supports the exploration of highly innovative, untested, exploratory, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 GBMRP Hypothesis Development focus areas: Drug Delivery Biomarkers Submission of a Letter of Intent is required prior to full application submission. Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, logical reasoning and a sound scientific rationale for the proposed work must be described. Clinical research is allowed. Clinical trials are NOT allowed. Animal studies are permitted. Partnering PI Option: Supports synergistic partnerships between two investigators (termed the Initiating PI and Partner PI) collaborating on a single application. 	 The maximum allowable funding for the entire period of performance is: Single PI Option: \$200,000 for direct costs. Partnering PI Option: \$300,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 2 years. 	Pre-Application (Letter of Intent): November 6, 2024 5:00 p.m. Eastern time Application: November 20, 2024 11:59 p.m. Eastern time
Resource Development Award Go to: Program Announcement General Application Instructions Instructions Grants.gov Funding Opportunity Number: HT942524GBMRPRDA HT942524GBMRPRDA	Independent investigators at all career levels (or equivalent). Early-career investigators (defined as independent, non-mentored investigators at least 2 years beyond their last training position) are encouraged to apply.	 Supports product-driven research focused on the advancement of preclinical model systems (in vitro and in vivo) that need further development, characterization, validation, or standardization. Submission of a Letter of Intent is required prior to full application submission. Preliminary data are required. Clinical research is allowed. Clinical trials are NOT allowed. Animal studies are permitted. A Resource Distribution Plan describing how the fully developed resource will be made available to the scientific and/or clinical community is required. 	 The maximum allowable funding for the entire period of performance is \$500,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 3 years. 	Pre-Application (Letter of Intent): November 6, 2024 5:00 p.m. Eastern time Application: November 20, 2024 11:59 p.m. Eastern time